A review of antibiotics and psoriasis: induction, exacerbation, and amelioration

References

• Takeshita J, Shin DB, Ogdie A, et al. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018 Aug;138(8):1726–1735. .
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Kim SC, Lee MP, et al. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019 May 10. DOI:10.1001/jamadermatol.2019.1121.
   Web of Science ®Google Scholar
• Ng CY, Huang YH, Chu CF, et al. Risks for Staphylococcus aureus colonization in patients with psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2017 Oct;177(4):967–977.
   PubMed Web of Science ®Google Scholar
• Dogan B, Karabudak O, Harmanyeri Y. Antistreptococcal treatment of guttate psoriasis: a controlled study. Int J Dermatol. 2008 Sep;47(9):950–952.
   PubMed Web of Science ®Google Scholar
• Caca-Biljanovska NG, V’lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J. 2002 Dec;43(6):707–712.
   PubMed Web of Science ®Google Scholar
• Saxena VN, Dogra J. Long-term use of penicillin for the treatment of chronic plaque psoriasis. Eur J Dermatol. 2005 Sep-Oct;15(5):359–362.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Shoda Y, Akiyama M. Generalized pustular psoriasis triggered by amoxicillin in monozygotic twins with compound heterozygous IL36RN mutations: comment on the article by Navarini et al. J Invest Dermatol. 2014 Feb;134(2):578–579.
   PubMed Web of Science ®Google Scholar
• Katz M, Seidenbaum M, Weinrauch L, et al. Penicillin-induced generalized pustular psoriasis. J Am Acad Dermatol. 1987;17:918–920.
   PubMed Web of Science ®Google Scholar
• Hernandez M, Simms-Cendan J, Zendell K. Guttate psoriasis following streptococcal vulvovaginitis in a five-year-old girl. J Pediatr Adolesc Gynecol. 2015 Oct;28(5):e127–9.
   PubMed Web of Science ®Google Scholar
• Moore LJ, Pridmore AC, Lee ME, et al. Induction of pro-inflammatory cytokine release by human macrophages during exposure of Streptococcus pneumoniae to penicillin is influenced by minimum inhibitory concentration ratio. Int J Antimicrob Agents. 2005 Sep;26(3):188–196.
   PubMed Web of Science ®Google Scholar
• Zheng J, Gao Y, Yi X, et al. A case of ceftriaxone-induced acute generalized exanthematous Pustulosis/generalized pustular psoriasis overlap. Case Rep Dermatol. 2018 Mar 27;10(1):69–75.
   PubMed Web of Science ®Google Scholar
• Zanvit P, Konkel JE, Jiao X, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat Commun. 2015 Sep;29(6):8424. .
   Google Scholar
• Brinkmeier T, Frosch PJ. Oral antibiotics with antiinflammatory/immunomodulatory effects in the treatment of various dermatoses. Hautarzt. 2002 Jul;53(7):456–465.
   PubMed Web of Science ®Google Scholar
• Alzolibani AA, Zedan K. Macrolides in chronic inflammatory skin disorders. Mediators Inflamm. 2012;2012:159354. .
   PubMedGoogle Scholar
• Polat M, Lenk N, Yalcin B, et al. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol. 2007 May;32(3):295–297.
   PubMed Web of Science ®Google Scholar
• Saxena VN, Dogra J. Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial. Eur J Dermatol. 2010 May-Jun;20(3):329–333.
   PubMed Web of Science ®Google Scholar
• Ohshima A, Takigawa M, Tokura Y. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement. Eur J Dermatol. 2001 Sep-Oct;11(5):410–415.
   PubMed Web of Science ®Google Scholar
• Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol. 2000 Aug;27(8):508–512.
   PubMedGoogle Scholar
• Tamaki K. Antipruritic effect of macrolide antibiotics. J Dermatol. 2000 Jan;27(1):66–67.
   PubMedGoogle Scholar
• Konno S, Adachi M, Asano K, et al. Inhibition of human T-lymphocyte activation by macrolide antibiotic, roxithromycin. Life Sci. 1992;51(24):PL231–6.
   PubMed Web of Science ®Google Scholar
• Wakita H, Tokura Y, Furukawa F, et al. The macrolide antibiotic, roxithromycin suppresses IFN-gamma-mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull. 1996 Feb;19(2):224–227.
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004 Nov;117(Suppl 9A):5S–11S.
   PubMedGoogle Scholar
• Huang SW, Chen YJ, Wang ST, et al. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice. J Dermatol Sci. 2016 Oct;84(1):59–70.
   PubMed Web of Science ®Google Scholar
• Zaiem A, Mebazaa A, Lakhoua G, et al. Clarithromycin induced psoriasis in a 37-year old man. Curr Drug Saf. 2014 Mar;9(1):77–78.
   PubMedGoogle Scholar
• Jackson N. Fusidic acid treatment in psoriasis. Lancet. 1971 Sep 25;298(7726):712.
   Google Scholar
• Levantine AV, Baker H. Fusidic acid treatment in psoriasis. Lancet. 1971 Sep 18;2(7725):661.
   PubMed Web of Science ®Google Scholar
• Hall-Smith P. Fusidic-acid treatment in psoriasis. Lancet. 1971 Sep 4;2(7723):544.
   PubMed Web of Science ®Google Scholar
• Voetmann E. Fusidic acid treatment in psoriasis. Lancet. 1971 Aug 21;2(7721):435.
   PubMed Web of Science ®Google Scholar
• Nyfors A. Fucidin in psoriasis. A double-blind study of twenty psoriatics over two periods of four weeks each. Dermatologica. 1973;146(5):281–284.
   PubMedGoogle Scholar
• Tsankov N, Botev-Zlatkov N, Lazarova AZ, et al. Psoriasis and drugs: influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol. 1988 Oct;19(4):629–632.
   PubMed Web of Science ®Google Scholar
• Tsankov NK, Vassileva SV, Lazarova AZ, et al. Onset of psoriasis coincident with tetracycline therapy. Australas J Dermatol. 1988;29(2):111–112.
   PubMedGoogle Scholar
• Bergner T, Przybilla B. Psoriasis and tetracyclines. J Am Acad Dermatol. 1990 Oct;23:770–771.
   PubMed Web of Science ®Google Scholar
• Cullen S, Crounse R. Cutaneous pharmacology of the tetracyclines. J Invest Dermatol. 1965;45:263–268.
   PubMed Web of Science ®Google Scholar
• Forster S, Ilderton E, Summerly R, et al. The level of phospholipase A2 activity is raised in uninvolved epidermis of psoriasis. Br J Dermatol. 1983;108:103–105.
   PubMed Web of Science ®Google Scholar
• Retser E, Schied T, Skryabin BV, et al. Doxycycline-induced expression of transgenic human tumor necrosis factor α in adult mice results in psoriasis-like arthritis. Arthritis Rheum. 2013 Sep;65(9):2290–2300.
   PubMedGoogle Scholar
• Ständer S, Ständer M, Thomas P, et al. Psoriasis migrans: erythema migrans as Koebner phenomenon in psoriasis. Hautarzt. 2016 Jul;67(7):549–552.
   PubMed Web of Science ®Google Scholar
• Dogra L, Saxena VN, Dogra J, et al. A controlled trial of oral rifampin in chronic plaque psoriasis. Br J Med Med Res. 2014;4(17):3248–3254.
   Google Scholar
• Tsankov N, Grozdev I. Rifampicin–a mild immunosuppressive agent for psoriasis. J Dermatolog Treat. 2011 Apr;22(2):62–64.
   PubMed Web of Science ®Google Scholar
• Tsankov N, Grozdev I, Kkzandjieva J. Old drug–new indication. Rifampicin in psoriasis. J Dermatolog Treat. 2006;17(1):18–23.
   Google Scholar
• Tsankov N, Krasteva M. Rifampicin therapy in severe forms of psoriasis. J Dermatol Treat. 1992;3:69–71.
   Google Scholar
• Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagicytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int Immunopharmacol. 2003;3:513–522.
   PubMed Web of Science ®Google Scholar
• Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother. 2004;16:357–361.
   PubMed Web of Science ®Google Scholar
• Paunescu E. In vivo and in vitro suppression of humoral and cellular response by rifampicin. Nature. 1970;229:1188–1189.
   Google Scholar
• Esposito M, Saraceno R, Schipani C, et al. Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis. J Infect. 2008 Jul;57(1):90–92.
   PubMed Web of Science ®Google Scholar
• Redighieri IP, Maia Tde C, Nadal MA, et al. Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report. An Bras Dermatol. 2011 Jul-Aug;86(4 Suppl 1):S141–3.
   PubMed Web of Science ®Google Scholar
• Chiriac A, Ferariu D, Solovan C, et al. Improvement in severe psoriasis associated with isoniazid treatment. Dermatol Online J. 2014 May 16;20(5):22617.
   PubMedGoogle Scholar
• Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J Am Acad Dermatol. 1986;14:761–764.
   PubMed Web of Science ®Google Scholar
• Vincent F, Ross JB, Dalton M, et al. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol. 1992;26:458–461.
   PubMed Web of Science ®Google Scholar
• Raza N, Usman M, Hameed A. Chronic plaque psoriasis: streptococcus pyogenes throat carriage rate and therapeutic response to oral antibiotics in comparison with oral methotrexate. J Coll Physicians Surg Pak. 2007 Dec;17(12):717–720.
   PubMed Web of Science ®Google Scholar
• McFadyen T, Lyell A. Successful treatment of generalized pustular psoriasis (von Zumbusch) by systemic antibiotics controlled by blood culture. Br J Dermatol. 1971 Sep;85(3):274–276.
   PubMed Web of Science ®Google Scholar
• Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018 Apr;178(4):854–862.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011 Aug 18;365(7):620–628.
   PubMed Web of Science ®Google Scholar
• Wang TS, Chiu HY, Hong JB, et al. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016 Jan;308(1):55–63.
   PubMed Web of Science ®Google Scholar
• Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014 Jun;74(3):187–192.
   PubMed Web of Science ®Google Scholar
• Proksa B, Uhrín D, Kovácik V, et al. Identity of the antibiotic ramihyphin A and cyclosporin A. Folia Microbiol (Praha). 1991;36(2):141–143.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Chan WH, Hinojosa T, et al. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. Clin Dermatol. 2019 Mar - Apr;37(2):160–166. .
   PubMed Web of Science ®Google Scholar
• MJE V, DB K, Pretorius E. Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol. 2019 Feb;9:7.
   PubMed Web of Science ®Google Scholar
• Thio HB. The microbiome in psoriasis and psoriatic arthritis: the skin perspective. J Rheumatol Suppl. 2018 Jun;94:30–31.
   PubMedGoogle Scholar
• Dudek-Wicher RK, Junka A, Bartoszewicz M. The influence of antibiotics and dietary components on gut microbiota. Prz Gastroenterol. 2018;13(2):85–92.
   PubMed Web of Science ®Google Scholar
• Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017 Sep;279(1):90–105.
   PubMed Web of Science ®Google Scholar